Pfizer (NYSE: PFE) — Perfil da empresa, notícias e dados financeiros
Pfizer is a global biopharmaceutical company focused on developing medicines and vaccines for various diseases, enhancing global health.
Pfizer
Pfizer is a biopharmaceutical company engaged in the research, development, manufacture, distribution, and commercialization of healthcare products worldwide. The company operates across several primary therapeutic areas, including oncology, vaccines, inflammation and immunology, internal medicine, and anti-infectives. Its product portfolio encompasses small-molecule drugs, biologics, gene therapies, and preventive vaccines supplied to healthcare providers, hospitals, and pharmacies globally. Headquartered in the United States, the organization conducts research and development activities and operates extensive manufacturing and supply chain networks servicing patients and medical systems in international markets.
Resumo
Operações
Produtos e/ou serviços de Pfizer
- Oncology: Targeted therapies, immunotherapies, and antibody-drug conjugates for solid tumors and hematological malignancies, delivering small molecules and biologics across broad global commercial markets to address complex cancer indications and improve clinical outcomes.
- Vaccines: Preventive and therapeutic immunization solutions for viral and bacterial pathogens, including pneumococcal, respiratory, and meningococcal diseases, backed by large-scale global biopharmaceutical manufacturing and distribution infrastructure servicing pediatric and adult populations.
- Inflammation and Immunology: Molecular treatments targeting chronic autoimmune and inflammatory diseases in gastroenterology, dermatology, and rheumatology, providing targeted biologics and oral small-molecule inhibitors designed to modulate complex immune response pathways in affected patients.
- Internal Medicine: Pharmaceutical therapies for cardiovascular, metabolic, and renal conditions, including oral treatments targeting type 2 diabetes, lipid disorders, obesity, and systemic vascular diseases distributed across primary care settings and global retail pharmacy networks.
- Anti-Infectives and Hospital Products: Sterile injectable anti-infectives, systemic anti-fungals, and critical care hospital therapies, supplying acute care facilities and healthcare institutions with essential therapeutic options for severe inpatient infectious and systemic medical conditions.
- Contract Manufacturing Services: Custom active pharmaceutical ingredient synthesis, specialized drug formulation development, bioprocessing, and sterile liquid fill-finish services provided to external biopharmaceutical and biotechnology commercial partners across major global healthcare manufacturing facilities.
equipe executiva do Pfizer
- Albert BourlaChairman of the Board & CEO
- Chris BoshoffChief Scientific Officer and President of Research & Development
- Douglas M. LanklerExecutive VP & Chief Legal Officer
- Aamir MalikExecutive VP & Chief U.S. Commercial Officer
- Cecile GueganInterim CFO & Executive VP
- Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer
- Dennis P. HancockExecutive VP & Chief Information Officer
- Francesca M. DeMartinoChief Investor Relations Officer
- Payal Sahni BecherChief People Experience Officer & Executive VP
- Michael S. VincentSenior VP and Chief Scientific Officer of Inflammation & Immunology
Últimas notícias sobre a Pfizer
Pfizer Q3 earnings top forecasts as revenue reaches $16.58B
United StatesPfizer reports tilrekimig Phase 2 trial success
United StatesNurix receives $7 million milestone payment from Pfizer collaboration
United StatesPfizer presents 45 oncology abstracts at ESMO 2026
United StatesPfizer BioNTech gets Canada vaccine authorization
United StatesPfizer, Valneva Lyme vaccine enters EMA review
United States
Histórico de dividendos
Dividendos por ação pagos pela Pfizer, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $1.7200 |
| FY2025 | — | — | — | $1.7200 |
| FY2024 | — | — | — | $1.6800 |
| FY2023 | — | — | — | $1.6400 |
| FY2022 | — | — | — | $1.6000 |
Principais indicadores financeiros
Resultados divulgados pela Pfizer, em USD.
- Cap. de mercado
- 167,3 bi
- Receita (TTM)
- 63,6 bi
- P/L
- 41.9
- LPA (diluído, TTM)
- 0.7
- Dividend yield
- 7.4%
- Margem de lucro
- 6.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 62,6 bi | 17,4 bi | 7,8 bi | |
| 63,6 bi | 14,9 bi | 8 bi | |
| 59,6 bi | 4,4 bi | 2,1 bi | |
| 101,2 bi | 38,1 bi | 31,4 bi |